A Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease
NCT06612268 · Hibiscus 2 Phase 3Recruiting
- Lead sponsor
- Novo Nordisk A/S (Industry)
- Enrollment
- 510 (estimated)
- Start date
- 17 Feb 2025
- Primary completion
- 27 Aug 2027 (estimated)
- Study completion
- 12 Aug 2029
- Last update posted
- 17 Sep 2026
Design
- Study type
- Interventional
- Primary purpose
- Treatment
- Allocation
- Randomized
- Intervention model
- Parallel
- Masking
- Quadruple
- Arms
- 2
Interventions
- Etavopivat Drug
- Placebo Drug
Conditions and primary outcome
- Sickle Cell Disease
Primary outcome
Number of adjudicated Vaso-occlusive crisis (VOC) events with a medical contact (Baseline (week 0) to week 52)
Posted results on ClinicalTrials.gov
Results posted on ClinicalTrials.gov: No
Results from company and journal sources
No editor-confirmed results are on record for this study.
Publications
No PubMed citation lists NCT06612268.
CT-VCA trial quality
About CT-VCALoading CT-VCA scores…
Data integrity
Compare what the registry, company releases, FDA documents and publications say about this study.
Drugs on HealthTrade
Source
- NCT06612268 on ClinicalTrials.gov (opens in a new tab) Licence: public-domain. Read
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Listing a study does not mean NLM has evaluated it.
Nothing on this page is medical or investment advice.